- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07931053
Use of mHealth Application and Education to Increase Appropriateness of Thromboprophylaxis in Patients With Cancer
mHealth-supported Education Improves Thromboprophylaxis Appropriateness in Solid Tumors
Doctors will use a mHealth application to evaluate the risk of thrombosis and bleeding in patients with cancer.
Przegląd badań
Status
Interwencja / Leczenie
Szczegółowy opis
This information will be shared with the patients to make an informed decision of using low molecular weight prophylaxis with heparin in case of high risk thrombosis a low-moderate risk of bleeding
Typ studiów
Zapisy (Rzeczywisty)
Faza
- Nie dotyczy
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Alicante
-
Villajoyosa, Alicante, Hiszpania, 03570
- Hospital Marina Baixa
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria:
- Age 18 years or older, and
- Recent diagnosis of a solid tumor or disease progression after partial or complete remission, and.
- Starting a new course of systemic anticancer therapy (chemotherapy, targeted therapy, hormone therapy, or immunotherapy) planned for at least 3 months
Exclusion Criteria:
- High risk of bleeding (e.g., advanced liver disease with coagulopathy), or
- Life expectancy under 3 months, or
- Hematologic malignancies, or
- Estimated glomerular filtration rate below 30 mL/min/1.73 m², or
- Platelet count below 50,000/mm³, or
- Body weight below 40 kg, or
- Current anticoagulant use.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Badania usług zdrowotnych
- Przydział: Nielosowe
- Model interwencyjny: Zadanie sekwencyjne
- Maskowanie: Brak (otwarta etykieta)
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
|---|---|
|
Brak interwencji: Control group (preintervention)
Inclusion criteria:
Exclusion criteria:
In the preintervention period, we reviewed the electronic medical records of patients with a recent cancer diagnosis who were seen between January and June 2024. |
|
|
Aktywny komparator: postintervention
After using the mHealth application, the treating physician made the final decision regarding use of thromboprophylaxis after considering risk of thromboembolic disease, bleeding risk, renal function, drug interactions, and patient preferences. Postintervention period. For patients with cancer seen between January and June 2025, we collected the same variables from the electronic medical records as in the preintervention period. We selected the same calendar months to control for seasonality and enhance comparability between periods |
Physicians from the Internal Medicine and Oncology divisions attended a 2-hour session reviewing current guidelines for thromboprophylaxis in patients with cancer, followed by training on the mHealth TEVAPP application. TEVAPP is a web-based calculator of venous thromboembolism (VTE) risk scores for patients with cancer, developed by the Spanish Society of Medical Oncology (SEOM) (Spain; https://tevapp.es/; accessed December 15, 2024). The application was used to support clinical decision-making by integrating available clinical, laboratory, and treatment information at the initial visit before the initiation of a new systemic regimen. TEVAPP is a web-based calculator of VTE risk scores for patients with cancer, developed by SEOM (Spain; https://tevapp.es/; accessed December 15, 2024). It was used to support clinical decisions by integrating available clinical, laboratory, and treatment information at the initial visit before a new systemic regimen |
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Proprtion of patients with appropriate thromboprophylaxis use
Ramy czasowe: From first visit to oncology clinic up to three month of follow up
|
The primary outcome was the proportion of patients with appropriate prescription of thromboprophylaxis from the first medical oncology visit in the pre- and postintervention periods. The appropriateness of thromboprophylaxis was determined according to clinical practice guideline recommendations. Thromboprophylaxis was considered appropriate when weight-adjusted enoxaparin was prescribed for patients at intermediate or high thrombotic risk (6-month VTE probability >8%) and low bleeding risk, in the absence of other contraindications. Low bleeding risk was defined as an IMPROVE score <7 for patients hospitalized within the previous 30 days, or a Hokusai score <3 for nonhospitalized patients. In the version of TEVAPP used, the latter corresponded to fewer than 60% of bleeding risk factors. Withholding thromboprophylaxis was considered appropriate for patients at low thrombotic risk or with contraindications to anticoagulation. |
From first visit to oncology clinic up to three month of follow up
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Incidence of venous thromboembolic disease
Ramy czasowe: From first visit the the Oncology Clinic up to three months of follow-up
|
We compared the incidence of VTE disease in the pre- and postintervention periods. VTE is suspected based on clinical symptoms and signs and confirmed with objective testing. The diagnostic approach includes assessment of pretest clinical probability, selective D-dimer testing, and imaging. Suspected DVT: Clinical probability is estimated using the 2-level Wells score. Patients with a likely score (≥2 points) should undergo proximal leg-vein compression ultrasonography, preferably with Doppler assessment; D-dimer may be used selectively when ultrasound is negative or clinical probability is low. Suspected PE: Clinical probability is estimated using a validated score such as the Wells score. Definitive diagnosis is usually made with computed tomography pulmonary angiography (CTPA); a ventilation-pe |
From first visit the the Oncology Clinic up to three months of follow-up
|
|
Incidence of bleeding
Ramy czasowe: From first visit the the Oncology Clinic up to three months of follow-up
|
We compared the bleeding events in the pre- and postintervention periods classified according to the International Society on Thrombosis and Haemostasis (ISTH) criteria. Major bleeding was defined as fatal bleeding, symptomatic bleeding in a critical site or organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, or pericardial bleeding, or intramuscular bleeding with compartment syndrome), or bleeding associated with a hemoglobin decrease of ≥2 g/dL or transfusion of ≥2 units of whole blood or packed red blood cells. Clinically relevant non-major bleeding was defined as overt bleeding not meeting major bleeding criteria but requiring hospitalization, medical or surgical intervention, or interruption or modification of anticoagulant therapy |
From first visit the the Oncology Clinic up to three months of follow-up
|
|
Incidence of death
Ramy czasowe: From first visit the the Oncology Clinic up to three months of follow-up
|
We compared all-cause mortality in the pre- and postintervention periods. All-cause mortality was defined as death from any cause occurring during the study follow-up period. |
From first visit the the Oncology Clinic up to three months of follow-up
|
Współpracownicy i badacze
Śledczy
- Główny śledczy: Javier Ena, MD, Hospital Marina Baixa
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- Univeridad Miguel Hernandez
- UGP-24-212 (Inny numer grantu/finansowania: Fundación Eugenio Rodriguez Pascual)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
Upon reasonable request with patient de-identification
Ramy czasowe udostępniania IPD
October 2026, to October 2027
Kryteria dostępu do udostępniania IPD
Javier Ena, MD. Personal computer
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- SOK ROŚLINNY
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .